论文部分内容阅读
目的：探索抗人纤维蛋白单链抗体链亲合素融合蛋白的应用前景。方法：构建抗人纤维蛋白单链抗体ｓｃＦｖ８Ｅ５基因与链亲和素基因的重组表达载体ｐＳＴＥ２８Ｅ５ ，表达的融合蛋白可特异性识别人纤维蛋白，同时有生物素的结合位点。转化ＪＭ１０９ 后用ＩＰＴＧ 诱导表达，ＥＬＩＳＡ 观察融合蛋白的稳定性。结果：抗人纤维蛋白单链抗体链亲合素融合蛋白稳定性好，可耐受至少２ ｗ ，４ ℃保存、数次反复冻融或一定时间的３７ ℃孵育。它能与大鼠和豚鼠的纤维蛋白结合，而与猪纤维蛋白反应不明显。结论：抗人纤维蛋白单链抗体链亲和素融合蛋白适用于大鼠或豚鼠血栓病模型，是临床前研究的有用材料。
Objective: To explore the application prospect of anti-human fibrin scFv-streptavidin fusion protein. Methods: Construction of anti-human fibrin scFv 8E5 gene and streptavidin gene recombinant expression vector pSTE2 8E5, the expression of the fusion protein can specifically identify human fibrin, biotin binding sites. JM109 transformed with IPTG induced expression, ELISA to observe the stability of the fusion protein. Results: The anti-human fibrin scFv-streptavidin fusion protein has good stability and can tolerate at least 2 weeks, 4 ℃ preservation, repeated freeze-thaw cycles or incubation at 37 ℃ for a certain period of time. It binds to the fibrin of rats and guinea pigs, but not to the pig fibrin. Conclusion: The anti-human fibronectin streptavidin fusion protein is suitable for rat or guinea pig thrombosis model and is a useful material in preclinical studies.